Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 23Unknown 6Withdrawn 3Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Liver Neoplasms 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Trastuzumab 78Capecitabine 59Cyclophosphamide 54Paclitaxel 52Docetaxel 50Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 26exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Taxes 17Everolimus 17Epirubicin 15pertuzumab 13Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13palbociclib 12Magnetic Resonance Spectroscopy 12liposomal doxorubicin 11atezolizumab 11Filgrastim 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × High-Energy Shock Waves × Clear all
NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

University of Nebraska

Phase 2 Terminated
3 enrolled 6 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡